DellOsso L, Bonelli C, Nardi B, Giovannoni F, Pronesti C, Cremone I
Brain Sci. 2024; 14(1).
PMID: 38275523
PMC: 10813979.
DOI: 10.3390/brainsci14010103.
Grace A, Uliana D
Int J Mol Sci. 2023; 24(15).
PMID: 37569748
PMC: 10418544.
DOI: 10.3390/ijms241512374.
Dedic N, Dworak H, Zeni C, Rutigliano G, Howes O
Int J Mol Sci. 2021; 22(24).
PMID: 34947997
PMC: 8704992.
DOI: 10.3390/ijms222413185.
Gomes F, Grace A
Int J Mol Sci. 2021; 22(9).
PMID: 33922888
PMC: 8123139.
DOI: 10.3390/ijms22094467.
Dragoi A, Radulescu I, Nasui B, Pop A, Varlas V, Trifu S
Brain Sci. 2020; 10(11).
PMID: 33187329
PMC: 7697202.
DOI: 10.3390/brainsci10110840.
Drug rechanneling: A novel paradigm for cancer treatment.
Kaushik I, Ramachandran S, Prasad S, Srivastava S
Semin Cancer Biol. 2020; 68:279-290.
PMID: 32437876
PMC: 7786449.
DOI: 10.1016/j.semcancer.2020.03.011.
Identifying the Cellular Correlates of Antipsychotic Drugs.
Joshi R, Panicker M
eNeuro. 2019; 5(5).
PMID: 30713996
PMC: 6354787.
DOI: 10.1523/ENEURO.0220-18.2018.
Childhood-Onset Schizophrenia: Insights from Induced Pluripotent Stem Cells.
Hoffmann A, Ziller M, Spengler D
Int J Mol Sci. 2018; 19(12).
PMID: 30513688
PMC: 6321410.
DOI: 10.3390/ijms19123829.
Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.
de Berardis D, Rapini G, Olivieri L, Di Nicola D, Tomasetti C, Valchera A
Ther Adv Drug Saf. 2018; 9(5):237-256.
PMID: 29796248
PMC: 5956953.
DOI: 10.1177/2042098618756261.
Potential drug targets and treatment of schizophrenia.
Kumar A, Yadav M, Parle M, Dhingra S, Dhull D
Inflammopharmacology. 2017; 25(3):277-292.
PMID: 28353125
DOI: 10.1007/s10787-017-0340-5.
Zebrafish behavioral profiling identifies multitarget antipsychotic-like compounds.
Bruni G, Rennekamp A, Velenich A, McCarroll M, Gendelev L, Fertsch E
Nat Chem Biol. 2016; 12(7):559-66.
PMID: 27239787
PMC: 4912417.
DOI: 10.1038/nchembio.2097.
Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment.
Zink M
Adv Med. 2015; 2014:317980.
PMID: 26556409
PMC: 4590963.
DOI: 10.1155/2014/317980.
Quo Vadis Clozapine? A Bibliometric Study of 45 Years of Research in International Context.
Lopez-Munoz F, Sanz-Fuentenebro J, Rubio G, Garcia-Garcia P, Alamo C
Int J Mol Sci. 2015; 16(9):23012-34.
PMID: 26404263
PMC: 4613349.
DOI: 10.3390/ijms160923012.
What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?.
Becker R, Seeman M, Greig N, Lahiri D
Lancet Psychiatry. 2015; 2(8):756-764.
PMID: 26249306
PMC: 5161453.
DOI: 10.1016/S2215-0366(15)00214-X.
Second-generation antipsychotics and extrapyramidal adverse effects.
Divac N, Prostran M, Jakovcevski I, Cerovac N
Biomed Res Int. 2014; 2014:656370.
PMID: 24995318
PMC: 4065707.
DOI: 10.1155/2014/656370.
Antipsychotic dosing: found in translation.
Remington G, Fervaha G, Foussias G, Agid O, Turrone P
J Psychiatry Neurosci. 2014; 39(4):223-31.
PMID: 24467943
PMC: 4074233.
DOI: 10.1503/jpn.130191.
Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors.
Schirmbeck F, Zink M
Front Pharmacol. 2013; 4:99.
PMID: 23950745
PMC: 3738863.
DOI: 10.3389/fphar.2013.00099.
Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia.
Maher K, Tan M, Tossell J, Weisinger B, Gochman P, Miller R
J Child Adolesc Psychopharmacol. 2013; 23(2):110-6.
PMID: 23510445
PMC: 3608018.
DOI: 10.1089/cap.2011.0136.
Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulness.
Johnsen E, Kroken R
Ther Adv Chronic Dis. 2013; 3(6):287-300.
PMID: 23342242
PMC: 3539262.
DOI: 10.1177/2040622312462275.
Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review.
Schirmbeck F, Zink M
Curr Neuropharmacol. 2012; 10(1):88-95.
PMID: 22942882
PMC: 3286851.
DOI: 10.2174/157015912799362724.
